文献速递淋巴瘤

TAFRO综合征是特发性多中心Castleman病的亚型吗

Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
PubMed 文献 · Am J Hematol · 2019-06-21

该回顾性多中心研究分析220例患者,比较特发性多中心Castleman病非特指型(iMCD-NOS)、TAFRO型iMCD及未证实iMCD的TAFRO综合征的临床特征。iMCD可分类为iMCD-NOS与TAFRO-iMCD两个不同亚型,后两者可能为同一实体,需及时诊断和强化治疗。

要点

  • iMCD-NOS组多克隆性高γ球蛋白血症,TAFRO组血小板减少、全身水肿等。
  • iMCD-NOS与TAFRO组5年生存率分别为100%与66.5%。
  • TAFRO-iMCD与未证实iMCD的TAFRO综合征临床特征无显著差异。

核心结论

  • iMCD可分为iMCD-NOS和TAFRO-iMCD两个不同亚型;TAFRO-iMCD与未证实iMCD的TAFRO综合征可能为同一实体,需及时诊断和强化治疗。

研究设计与样本

  • 多中心协作回顾性研究,从TAFRO综合征概念建立数据库提取220例患者,包括iMCD-NOS 87例、TAFRO-iMCD 63例、未证实iMCD的TAFRO综合征19例。

主要发现

  • 三组均表现贫血、低白蛋白血症及血清C反应蛋白和白细胞介素-6升高。
  • TAFRO-iMCD组与未证实iMCD的TAFRO综合征组临床、实验室及预后特征无显著差异。
  • iMCD-NOS组表现多克隆性高γ球蛋白血症。
  • iMCD-NOS组与TAFRO相关组5年生存率分别为100%与66.5%,后者最初数月明显下降。
  • iMCD-NOS与TAFRO-iMCD样本通常分别显示浆细胞型和混合型组织学。

临床怎么用

  • 作者认为TAFRO-iMCD与未证实iMCD的TAFRO综合征可能为同一实体,需及时诊断和强化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Castleman disease (CD) is a rare lymphoproliferative disorder that can be unicentric or multicentric. Multicentric CD (MCD) is further subdivided into human herpesvirus type-8-associated, POEMS syndrome-associated, and idiopathic (iMCD). TAFRO syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. The TAFRO syndrome is sometimes regarded as a subtype of iMCD (TAFRO-iMCD), whereas iMCD without TAFRO syndrome is considered "not otherwise specified" (iMCD-NOS). However, a proportion of patients with TAFRO syndrome have been diagnosed without lymph node biopsies (TAFRO syndrome without proven iMCD; TAFRO-w/op-iMCD). To clarify the clinical features of iMCD-NOS, TAFRO-iMCD, and TAFRO-w/op-iMCD, we retrospectively analyzed 220 patients extracted from the database of the Multicenter Collaborative Retrospective Study for Establishing the Concept of TAFRO Syndrome. The patients included 87 with iMCD-NOS, 63 with TAFRO-iMCD, and 19 with TAFRO-w/op-iMCD. Patients in all three groups exhibited anemia, hypoalbuminemia, and elevated serum C-reactive protein and interleukin-6 levels. No significant differences in clinical, laboratory, and prognostic features were noted between the TAFRO-iMCD, and TAFRO-w/op-iMCD groups. However, the iMCD-NOS group exhibited polyclonal hyper-γ-globulinemia. The five-year survival rates of patients in the iMCD-NOS and TAFRO-involved groups were 100% and 66.5%, respectively (dropping markedly during the first few months in the latter). The iMCD-NOS and the TAFRO-iMCD samples typically showed plasma cell and mixed-type histologies, respectively. Thus, iMCD can be classified into two distinct subtypes, iMCD-NOS and TAFRO-iMCD. As such, TAFRO-iMCD and TAFRO-w/op-iMCD may be considered the same entity, requiring prompt diagnosis and intensive care.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019. PMID: 31222819. doi:10.1002/ajh.25554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。